HEPA vs. EFTR, UPC, VCNX, KTTA, CANF, CYCN, BNOX, PCSA, RNAZ, and VIRI
Should you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include eFFECTOR Therapeutics (EFTR), Universe Pharmaceuticals (UPC), Vaccinex (VCNX), Pasithea Therapeutics (KTTA), Can-Fite BioPharma (CANF), Cyclerion Therapeutics (CYCN), Bionomics (BNOX), Processa Pharmaceuticals (PCSA), TransCode Therapeutics (RNAZ), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry.
eFFECTOR Therapeutics (NASDAQ:EFTR) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Hepion Pharmaceuticals' return on equity of 0.00% beat eFFECTOR Therapeutics' return on equity.
57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 8.4% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, eFFECTOR Therapeutics and eFFECTOR Therapeutics both had 1 articles in the media. eFFECTOR Therapeutics' average media sentiment score of 1.89 beat Hepion Pharmaceuticals' score of 0.81 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.
eFFECTOR Therapeutics has higher revenue and earnings than Hepion Pharmaceuticals. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
eFFECTOR Therapeutics received 2 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote.
eFFECTOR Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 1,137.11%. Given Hepion Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe eFFECTOR Therapeutics is more favorable than Hepion Pharmaceuticals.
eFFECTOR Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500.
Summary
eFFECTOR Therapeutics beats Hepion Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Hepion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hepion Pharmaceuticals Competitors List
Related Companies and Tools
